http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Genentech to Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data in Relapsing and Primary Progressive Forms of Multiple Sclerosis at ECTRIMS
-
Foundation Medicine Announces Timing for Third Quarter 2017 Financial Results and Conference Call
-
Foundation Medicine Appoints Tom Civik as Chief Commercial Officer
-
Foundation Medicine Receives Approval from the State of New York for its FoundationACT Liquid Biopsy Assay
-
Foundation Medicine to Present Validation Data for Its Assay Measuring Tumor Mutational Burden in Blood (bTMB), a New, Non-Invasive Predictor of Response to Immunotherapy
-
Foundation Medicine to Present at the 2017 Wells Fargo Healthcare Conference
-
Cancer Treatment Centers of America® and Foundation Medicine® Join Forces to Advance Precision Cancer Treatment
-
Foundation Medicine Announces 2017 Second Quarter Results and Recent Highlights
-
Foundation Medicine Announces Timing for Second Quarter 2017 Financial Results and Conference Call
-
Chugai Deploys RaveX to Modernize Post-Marketing Surveillance
-
Genentech (RHHBY) Says New Data at EAN Shows Ocrevus Reduced Disease Progression in RMS and PPMS
-
New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
-
ASCO and Foundation Medicine Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR) Study
-
Foundation Medicine to Identify Patients Eligible for National Cancer Institute’s NCI-MATCH (Molecular Analysis for Therapy Choice) Study
-
Foundation Medicine to Present at Upcoming Investor Conferences
-
Foundation Medicine (FMI) And Its Collaborators to Present New Data at ASCO
-
Foundation Medicine and Its Collaborators to Present New Data at ASCO 2017 Supporting the Integration of Comprehensive Genomic Profiling (CGP) in Personalized Clinical Care in Oncology
-
Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights
-
New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis
-
Foundation Medicine Announces Timing for First Quarter 2017 Financial Results and Conference Call
-
Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis
-
Bristol-Myers Squibb (BMY), Foundation Medicine (FMI) Enter Pact to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents
-
Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents
-
Foundation Medicine (FMI) Receives Medicare Payment for Comprehensive Genomic Profiling Assay Used in NSCLC
-
Foundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer under a Local Coverage Determination for FoundationOne®, the Company’s Comprehensive Genomic Profiling Assay
-
Foundation Medicine to Present at Cowen and Company’s 37th Annual Healthcare Conference
-
Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook
-
Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2016 Financial Results and Conference Call
-
Foundation Medicine Reports Preliminary 2016 Results
-
Foundation Medicine (FMI) Says Troy Cox to Succeed Michael Pellini as CEO
-
Foundation Medicine Announces Executive Leadership Transition
-
Foundation Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference
-
Foundation Medicine (FMI) Announces FDA Approval of FoundationFocus, Companion Diagnostic for Rubraca
-
Foundation Medicine Receives FDA Approval of FoundationFocus™ CDxBRCA as a Companion Diagnostic for Rubraca™ (rucaparib) for the Treatment of Women with Ovarian Cancer
-
"Don't Guess. Test." Campaign Aims to Increase Awareness of Comprehensive Genomic Testing to Advance Precision Medicine in Lung Cancer
-
Genentech (RHHBY) to Make 60+ Presentations at ASH 2016; Will Include Phase III GALLIUM Study Data
-
Genentech Showcases New Clinical Data across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
-
Flatiron Health and Foundation Medicine Unveil Powerful Oncology Information Resource to Advance Precision Medicine
-
Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights
-
Genentech (RHHBY) Plans Presentation of New Actemra, Rituxan Data at 2016 ACR/ARHP Annual Meeting
-
Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
-
Foundation Medicine and Sarah Cannon Collaborate to Advance Personalized Medicine for Patients with Cancer
-
Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors
-
Boehringer Ingelheim joins The Leukemia & Lymphoma Society in groundbreaking precision medicine approach to treating acute myeloid leukemia
-
Foundation Medicine Announces Timing for Third Quarter 2016 Financial Results and Conference Call
-
Exelixis (EXEL) Announces Presentation of Cobimetinib, Vemurafenib, Atezolizumab Combo Phase 1b Data in BRAF V600
-
Exelixis (EXEL) Announces Encouraging Cabozantinib Combo Phase 1 Data in Genitourinary Tumors
-
Kite Pharma (KITE) Commences KTE-C19 Combo Phase 1b/2 Combination Study in DLBCL (RHHBY)
-
Roche's (RHHBY) Genentech Announces New Data from OCREVUS Phase 3 in MS
